Table 3 Treatment choice on the basis of platinum sensitivity status (all lines treatment)
From: A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
| Â | PLD (30 patients) | Other therapy (No PLD) 25 patients |
|---|---|---|
Platinum sensitive | 9 (30 %) | 8 (32%) |
Partially-platinum sensitive | 10 (33%) | 5 (20%) |
Platinum refractory | 11 (37 %) | 12 (48%) |